This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Jeffrey P. Koplan, MD, MPH; Stephen R. Preblud, MD

Am J Dis Child. 1982;136(4):362-364.

Abstract
• Applying benefit-cost analysis, we determined the savings in morbidity, mortality, and costs of mumps vaccination in the United States. Using reported mumps incidence rates in a model cohort of 1 million persons followed up for 30 years, mumps vaccination would prevent more than 74,000 cases of mumps and three deaths. Approximating the actual incidence rate of mumps, by assuming that 90% of people are infected by age 30 and 60% of these have had clinical illness, mumps vaccination would prevent more than 540,000 cases of mumps and 23 deaths. A mumps vaccination program, in which mumps was given as part of a measles-mumps-rubella combination, would reduce costs associated with mumps by more than 86%, with a benefit-cost ratio of 7.4:1, using reported incidence rates. The program has a benefit-cost ratio of 39:1 when approximations of actual mumps incidence are used in the analysis. Mumps vaccination is highly cost beneficial.

(Am J Dis Child 1982;136:362-364)

Author Affiliations
From the Office of Program Planning and Evaluation (Dr Koplan) and the Immunization Division, Center for Prevention Services (Dr Preblud), Centers for Disease Control, Atlanta.

Footnotes
Reprint requests to Office of Program Planning and Evaluation, Centers for Disease Control, Atlanta, GA 30333 (Dr Koplan).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Economic Evaluation of the 7-Vaccine Routine Childhood Immunization Schedule in the United States, 2001
Zhou et al.
Arch Pediatr Adolesc Med 2005;159:1136-1144.
ABSTRACT | FULL TEXT  

Commentary: Ongoing debate over the safety of the different mumps vaccine strains impacts mumps disease control
Fullerton and Reef
Int J Epidemiol 2002;31:983-984.
FULL TEXT  

Mumps and Rubella Eliminated From Finland
Peltola et al.
JAMA 2000;284:2643-2647.
ABSTRACT | FULL TEXT  

The Association Between Adequacy of Prenatal Care Utilization and Subsequent Pediatric Care Utilization in the United States
Kogan et al.
Pediatrics 1998;102:25-30.
ABSTRACT | FULL TEXT  

Cost Benefit Analysis of Monitoring Serum Vancomycin Concentrations in a Teaching Hospital
Oparaoji et al.
Journal of Pharmacy Practice 1997;10:122-126.
ABSTRACT  

Mumps--United States, 1985-1988
JAMA 1989;261:1702-1708.
 

Leads From the MMWR
JAMA 1987;257:3333-3341.
 

Decision Analysis: A Progress Report
KASSIRER et al.
ANN INTERN MED 1987;106:275-291.
ABSTRACT  

Leads from the MMWR
JAMA 1986;255:2265-2270.
 

Leads from the MMWR
JAMA 1984;252:2385-2386.
 

Leads from the MMWR
JAMA 1983;250:2599-2600.
 

Mumps Vaccine: Recommendation of the Immunization Practices Advisory Committee
ANN INTERN MED 1983;98:192-194.
ABSTRACT